Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07615010 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure
A Phase 2 study, sponsored by MiNK Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT07615010 is a Phase 2 study that is actively recruiting participants, run by MiNK Therapeutics. The registered enrollment target is 90 participants.
The verdict
NCT07615010, a Phase 2 study, is actively recruiting participants, sponsored by MiNK Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This clinical trial will evaluate the efficacy and safety of a single intravenous dose of agenT-797 administered in addition to standard of care (SOC), compared with placebo plus SOC, in reducing short-term mortality in adult participants with severe pneumonia and moderate to severe AHRF. All participants will receive SOC management for severe pneumonia and acute respiratory distress syndrome (ARDS).
Interventions
- DRUG Placebo
- DRUG Standard of Care (SOC)
- DRUG agenT-797
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-05-26 |
| Est. Completion | 2027-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07615010
The ClinicalTrials.gov registry entry for NCT07615010 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MiNK Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07615010 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07615010 about?
NCT07615010 is a clinical study titled "A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure". This clinical trial will evaluate the efficacy and safety of a single intravenous dose of agenT-797 administered in addition to standard of care (SOC), compared with placebo plus SOC, in reducing short-term mortality in adult participants with severe pneumonia and moderate to severe AHRF. All partic...
What is the current status of trial NCT07615010?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2026-05-26. Estimated completion is 2027-08.
What interventions are being tested in trial NCT07615010?
The interventions under investigation include: Placebo (DRUG), Standard of Care (SOC) (DRUG), agenT-797 (DRUG).
Who is sponsoring clinical trial NCT07615010?
This trial is sponsored by MiNK Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.